Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

83%

5 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 3

3(60.0%)

Phase 4

2(40.0%)

5Total

Phase 3(3)

Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT00257010Phase 3Completed

A 1-year Study in Adolescents to Assess the Long-term Safety of Almotriptan Malate When Treating Their Migraine Headaches

Role: lead

NCT01091051Phase 3Terminated

Safety and Efficacy of Ustekinumab in Patients With Palmo-Plantar Pustular Psoriasis or With Palmo-Plantar Pustulosis

Role: collaborator

NCT00307268Completed

Evaluating Clinical Outcomes of Treatment Effectiveness for Children and Adults With ADHD

Role: collaborator

NCT00210509Phase 4Completed

A Study of the Effectiveness and Safety of Almotriptan Versus Placebo in the Treatment of Migraine Headache

Role: lead

NCT00210483Phase 3Completed

A Study of 3 Dosage Strengths of Almotriptan Malate (AXERT®) in the Treatment of Acute Migraine in Adolescents

Role: lead

NCT00210496Phase 4Completed

Potential Impact (Benefit) of Preventative Treatment With Topamax on the Effectiveness of Axert in the Acute Treatment of Migraine

Role: lead

All 6 trials loaded